Demographic, clinical, and electrocardiographic characteristics of the study population according to the occurrence of primary or secondary end points during follow-up
. | . | Primary end point . | . | . | Secondary end point . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics . | All patients, N = 319 . | With events, N = 61 . | Without events, N = 258 . | P . | With events, N = 144 . | Without events, N = 175 . | P . | ||||
| Age, y | 65 ± 7 | 66 ± 10 | 65 ± 9 | NS | 66 ± 10 | 66 ± 7 | NS | ||||
| Male sex (%) | 235 (73) | 46 (77) | 189 (72) | NS | 116 (80) | 119 (68) | NS | ||||
| Height, cm | 168 ± 7 | 168 ± 7 | 168 ± 7 | NS | 169 ± 6 | 167 ± 7 | NS | ||||
| Weight, kg | 73 ± 12 | 73 ± 12 | 73 ± 13 | NS | 73 ± 11 | 72 ± 13 | NS | ||||
| Family history (%) | 106 (33) | 18 (30) | 88 (34) | NS | 45 (31) | 61 (34) | NS | ||||
| Current smokers (%) | 106 (33) | 23 (38) | 83 (32) | NS | 47 (32) | 59 (33) | NS | ||||
| Diabetes mellitus (%) | 60 (18) | 16 (26) | 44 (17) | NS | 36 (25) | 24 (13) | NS | ||||
| History of hypertension (%) | 155 (49) | 28 (45) | 127 (49) | NS | 76 (52) | 79 (45) | NS | ||||
| Hypercholesterolemia (%) | 108 (34) | 12 (17) | 96 (37) | .009 | 45 (31) | 63 (36) | NS | ||||
| Previous myocardial infarction (%) | 112 (35) | 24 (39) | 88 (34) | NS | 60 (41) | 52 (30) | .02 | ||||
| Previous angina (%) | 90 (28) | 21 (34) | 69 (26) | NS | 37 (25) | 53 (30) | NS | ||||
| Chronic treatment, n (%) | |||||||||||
| Aspirin | 312 (98) | 58 (95) | 254 (99) | NS | 142 (98) | 174 (99) | NS | ||||
| Ticlopidine | 4 (1) | 2 (3) | 2 (1) | NS | 2 (4) | 1 (1) | NS | ||||
| β-blockers | 261 (82) | 46 (75) | 215 (83) | NS | 117 (81) | 144 (82) | NS | ||||
. | . | Primary end point . | . | . | Secondary end point . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics . | All patients, N = 319 . | With events, N = 61 . | Without events, N = 258 . | P . | With events, N = 144 . | Without events, N = 175 . | P . | ||||
| Age, y | 65 ± 7 | 66 ± 10 | 65 ± 9 | NS | 66 ± 10 | 66 ± 7 | NS | ||||
| Male sex (%) | 235 (73) | 46 (77) | 189 (72) | NS | 116 (80) | 119 (68) | NS | ||||
| Height, cm | 168 ± 7 | 168 ± 7 | 168 ± 7 | NS | 169 ± 6 | 167 ± 7 | NS | ||||
| Weight, kg | 73 ± 12 | 73 ± 12 | 73 ± 13 | NS | 73 ± 11 | 72 ± 13 | NS | ||||
| Family history (%) | 106 (33) | 18 (30) | 88 (34) | NS | 45 (31) | 61 (34) | NS | ||||
| Current smokers (%) | 106 (33) | 23 (38) | 83 (32) | NS | 47 (32) | 59 (33) | NS | ||||
| Diabetes mellitus (%) | 60 (18) | 16 (26) | 44 (17) | NS | 36 (25) | 24 (13) | NS | ||||
| History of hypertension (%) | 155 (49) | 28 (45) | 127 (49) | NS | 76 (52) | 79 (45) | NS | ||||
| Hypercholesterolemia (%) | 108 (34) | 12 (17) | 96 (37) | .009 | 45 (31) | 63 (36) | NS | ||||
| Previous myocardial infarction (%) | 112 (35) | 24 (39) | 88 (34) | NS | 60 (41) | 52 (30) | .02 | ||||
| Previous angina (%) | 90 (28) | 21 (34) | 69 (26) | NS | 37 (25) | 53 (30) | NS | ||||
| Chronic treatment, n (%) | |||||||||||
| Aspirin | 312 (98) | 58 (95) | 254 (99) | NS | 142 (98) | 174 (99) | NS | ||||
| Ticlopidine | 4 (1) | 2 (3) | 2 (1) | NS | 2 (4) | 1 (1) | NS | ||||
| β-blockers | 261 (82) | 46 (75) | 215 (83) | NS | 117 (81) | 144 (82) | NS | ||||
NS indicates not significant.